Skip to main content

Animations

MJFF Publications

1621 - 1630 of 6451 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2021
  • 2022
  • 2021
  • 2021
  • 2021
  • 2021
  • 2022
  • 2022
  • Summary Details
    OPEN
    Title: Concerns about the European Academy's Recommendations and Guidelines Regarding Pallidotomy for Parkinson's Disease
    Journal Name: European Journal of Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1111/ene.15569
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Symposia
    Journal Name: European Journal of Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1111/ene.15461
    Citation Count: 4
  • Summary Details
    OPEN
    Title: Focused Workshops
    Journal Name: European Journal of Neurology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1111/ene.14970
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Deep learning for Parkinson’s disease symptom detection and severity evaluation using accelerometer signal
    Journal Name: ESANN 2022 proceedings
    Publisher: Ciaco - i6doc.com
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.14428/esann/2022.es2022-107
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Supplement (online only): Proceedings of the 14th Göttingen Meeting of the German Neuroscience Society 2021
    Journal Name: Neuroforum
    Publisher: Walter de Gruyter GmbH
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1515/nf-2021-2003
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30449-x
    Citation Count: 326
  • Summary Details
    OPEN
    Title: Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30489-0
    Citation Count: 136
  • Summary Details
    OPEN
    Title: Prehospital scales in acute ischaemic stroke management – Authors' reply
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00169-1
    Citation Count: 1
  • Global, in situ analysis of the structural proteome in individuals with Parkinson’s disease to identify a new class of biomarker
    2022
    Summary Details
    OPEN
    Title: Global, in situ analysis of the structural proteome in individuals with Parkinson’s disease to identify a new class of biomarker
    Journal Name: Nature Structural & Molecular Biology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s41594-022-00837-0
    Citation Count: 53
  • Deep brain stimulation for obsessive–compulsive disorder: a crisis of access
    2022
    Summary Details
    OPEN
    Title: Deep brain stimulation for obsessive–compulsive disorder: a crisis of access
    Journal Name: Nature Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1038/s41591-022-01879-z
    Citation Count: 78
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.